[Edaily Reporter KIM SAE-MI ] Peptron, Inc.(087010)has received approval for its domestic Phase 1 clinical trial plan (IND) for “PT403,” a once-monthly obesity treatment candidate.
Peptron, Inc. announced on the 19th that it received approval for the Phase 1 clinical trial plan for PT403 from the Ministry of Food and Drug Safety on the 18th. This comes approximately three months after the company submitted the IND application on August 25.
PT403 is an obesity treatment currently being developed for once-monthly administration, with the goal of reducing the frequency of dosing and improving patient convenience. In this clinical trial, PT403 will be administered as a single subcutaneous injection to 22 healthy adults to evaluate its safety, tolerability, and pharmacokinetic characteristics.
The trial will be conducted at the Clinical Trial Center of Chungnam National University Hospital using a randomized, placebo-controlled, double-blind design. It consists of three cohorts and includes an active reference group. The Safety Review Committee (SRC) will review safety and tolerability data from each dose group to determine whether to proceed with subsequent dose escalation.
The primary evaluation will comprehensively review adverse events, adverse events of special interest (AESI), clinical laboratory results, vital signs, electrocardiograms (ECGs), and injection site reactions. Safety endpoints will be analyzed exploratorily using descriptive statistics; no formal statistical hypothesis testing will be performed.
This clinical trial is designed to assess the initial safety and pharmacokinetic profile of PT403, which is intended for once-monthly administration; it is not a trial specifically designed to directly verify weight loss efficacy in obese patients.
The clinical trial period is 12 months from the date of approval by the Ministry of Food and Drug Safety (MFDS) and the Institutional Review Board (IRB), with an expected completion date of November 30 of next year.